Literature DB >> 17045367

A review of human vaccine research and development: malaria.

Marc P Girard1, Zarifah H Reed, Martin Friede, Marie Paule Kieny.   

Abstract

The last several years have seen significant progress in the development of vaccines against malaria. Most recently, proof-of-concept of vaccine-induced protection from malaria infection and disease was demonstrated in African children. Pursued by various groups and on many fronts, several other candidate vaccines are in early clinical trials. Yet, despite the optimism and promise, an effective malaria vaccine is not yet available, in part because of the lack of understanding of the types of immune responses needed for protection, added to the difficulty of identifying, selecting and producing the appropriate protective antigens from a parasite with a genome of well over five thousand genes and to the frequent need to enhance the immunogenicity of purified antigens through the use of novel adjuvants or delivery systems. Insufficient clinical trial capacity and normative research functions such as local ethical committee reviews also contribute to slow down the development process. This article attempts to summarize the state of the art of malaria vaccine development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17045367     DOI: 10.1016/j.vaccine.2006.09.074

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  49 in total

1.  Comparative Immunogenicities of full-length Plasmodium falciparum merozoite surface protein 3 and a 24-kilodalton N-terminal fragment.

Authors:  Maryam Imam; Yengkhom Sangeeta Devi; Akhilesh K Verma; Virander Singh Chauhan
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

Review 2.  Towards an effective malaria vaccine.

Authors:  Pedro Aide; Quique Bassat; Pedro L Alonso
Journal:  Arch Dis Child       Date:  2007-06       Impact factor: 3.791

3.  Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.

Authors:  Kazutoyo Miura; Hong Zhou; Ababacar Diouf; Samuel E Moretz; Michael P Fay; Louis H Miller; Laura B Martin; Mark A Pierce; Ruth D Ellis; Gregory E D Mullen; Carole A Long
Journal:  Clin Vaccine Immunol       Date:  2009-05-13

Review 4.  Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyond.

Authors:  Jerome P Vanderberg
Journal:  Vaccine       Date:  2008-10-28       Impact factor: 3.641

Review 5.  Platform for Plasmodium vivax vaccine discovery and development.

Authors:  Sócrates Herrera Valencia; Diana Carolina Rodríguez; Diana Lucía Acero; Vanessa Ocampo; Myriam Arévalo-Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

Review 6.  Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America.

Authors:  Myriam Arévalo-Herrera; Yezid Solarte; Catherin Marin; Mariana Santos; Jenniffer Castellanos; John C Beier; Sócrates Herrera Valencia
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

Review 7.  Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.

Authors:  Rajeev K Mehlotra; Cara N Henry-Halldin; Peter A Zimmerman
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

8.  Identification and characterization of merozoite surface protein 1 epitope.

Authors:  Satarudra Prakash Singh; Bhartendu Nath Mishra
Journal:  Bioinformation       Date:  2009-08-17

9.  Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.

Authors:  Meta Roestenberg; Ed Remarque; Erik de Jonge; Rob Hermsen; Hildur Blythman; Odile Leroy; Egeruan Imoukhuede; Soren Jepsen; Opokua Ofori-Anyinam; Bart Faber; Clemens H M Kocken; Miranda Arnold; Vanessa Walraven; Karina Teelen; Will Roeffen; Quirijn de Mast; W Ripley Ballou; Joe Cohen; Marie Claude Dubois; Stéphane Ascarateil; Andre van der Ven; Alan Thomas; Robert Sauerwein
Journal:  PLoS One       Date:  2008-12-18       Impact factor: 3.240

10.  A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.

Authors:  Bertrand Lell; Selidji Agnandji; Isabelle von Glasenapp; Sonja Haertle; Sunny Oyakhiromen; Saadou Issifou; Johan Vekemans; Amanda Leach; Marc Lievens; Marie-Claude Dubois; Marie-Ange Demoitie; Terrell Carter; Tonya Villafana; W Ripley Ballou; Joe Cohen; Peter G Kremsner
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.